EGFR and cancer: The proposed GE11-CUR/ICG-LPs could not only actively target EGFR overexpressed cancer cells but also enable selective drug release controlled by NIR light, to significantly enhance the drug concentration at tumor sites, which could significantly reduce the off-target effects of CUR.